Siblings with rare eye disorder ready for experimental UK treatment: A Christmas miracle
One familys' Christmas wishes came true after their two sons who suffer from a rare inherited eye disorder were given the green light to receive an experimental
Stay updated with breaking news from Amaurosis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
One familys' Christmas wishes came true after their two sons who suffer from a rare inherited eye disorder were given the green light to receive an experimental
A rare opportunity has arisen for Ciro Carrascull - but it's halfway across the world.
Variant, a company dedicated to developing innovative treatments for inherited eye orphan diseases, announces the decision of the European Commission to grant Orphan Drug Designation (ODD) for VAR002
European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis NR2E3), for the treatment of both retinitis pigmentosa (RP) and Leber Congenital amaurosis (LCA). The prevalence of RP in Europe is estimated at approximately 165,000 patients and the prevalence of LCA in Europe is estimated at approximately 40,000 patients. Globally, the number of people suffering from RP and LCA is estimated to be around 2.0 million and 0.2 million, respectively. "We believe the grant...